Gartner predicts that by 2028, at least 15% of day-to-day work decisions will be made autonomously through agentic AI, up from 0% in 2024. In addition, 33% of enterprise software applications will include agentic AI by 2028, up from less than 1% in 2024. [1] For pharma organisations, the implications extend well beyond general productivity. Agentic AI is the mechanism that converts a governed knowledge layer into an active research and intelligence infrastructure: systems that do not wait to be asked, but continuously monitor, synthesise, analyse, and alert, executing multi-step research workflows with a level of speed, coverage, and consistency that no manual process can replicate.
In January 2026, Merck and Google Cloud announced a partnership of up to $1 billion aimed at building an agentic AI ecosystem for Merck's research and regulatory operations, recognising that the competitive advantage in pharma will increasingly belong to organisations that can deploy AI not as a tool but as an autonomous research engine. [3] Pienomial's Knolens platform, as an enterprise knowledge & AI memory platform and agentic AI knowledge layer, provides the governed knowledge foundation that makes agentic pharma research safe, auditable, and deployable in GxP environments.[9]
1. What an AI Agent Actually Is: The Precise Definition
An AI agent is fundamentally different from an AI assistant. An assistant responds to prompts. An agent pursues goals. The distinction is operational: an agent can call external tools such as database queries, web searches, document retrievers, and analysis functions as part of its execution; decompose a complex goal into sub-tasks and execute them in sequence; maintain state across a multi-step workflow, tracking what it has done, what it has found, and what remains; and make conditional decisions based on intermediate results, adjusting its plan when early steps reveal unexpected information.[1]
In pharma research terms, the difference is the difference between asking an AI system to summarise the pembrolizumab NSCLC trial landscape and asking it to conduct a PRISMA-compliant systematic review of all pembrolizumab NSCLC trials from 2018 to 2026, extract efficacy and safety data from each included study, generate a PRISMA flow diagram with exclusion counts at each stage, and produce a structured evidence table in NICE submission format. The first is a query. The second is an agent task. Only an agent can execute it without human intervention at each step.
2. The Pharma Adoption Reality in 2026
The ZS Associates 2025 CDIO Outlook survey found that 45% of enterprise IT leaders in life sciences and 41% of R&D discovery leaders are actively targeting end-to-end workflow transformation with AI agents. [4] McKinsey estimates the potential annual value of AI in pharma R&D and manufacturing at $18 to $30 billion, and 67% of life sciences firms were running agentic AI pilots as of Q1 2026.[5]
However, Gartner also warns that over 40% of agentic AI projects will be cancelled by the end of 2027 due to escalating costs, unclear business value, or inadequate risk controls. [1] The organisations that fail are those treating agentic AI as a tool deployment problem rather than an architecture problem. The organisations that succeed are those that build agentic workflows on a governed knowledge foundation, where the agent has access to verified, structured, source-attributed data rather than unstructured document repositories or the open web. This architectural distinction is the primary determinant of whether agentic pharma AI delivers value or creates regulatory risk.
3. Four High-Value Agentic AI Use Cases in Pharma Research
Four use cases in pharma research demonstrate the transformational value of agentic AI operating on a governed knowledge layer, as distinct from a simple LLM assistant or a RAG system.[6]
Use Case 1, CI Monitoring Agent: An agent continuously monitors ClinicalTrials.gov, EudraCT, conference abstract databases, regulatory filing records, and trade press for signals relevant to a defined competitive intelligence scope. Actions taken autonomously: ingesting new signals, classifying by signal type and strategic priority, retrieving relevant competitive context from the knowledge layer, and generating a structured alert with impact assessment. Without the agent: a team of analysts manually checking sources on a scheduled basis, with coverage gaps and days to weeks of latency. With the agent: 24-hour monitoring across all sources, with analyst time concentrated on strategic interpretation rather than data collection.
Use Case 2, SLR Execution Agent: Given a PICOTS framework and a target database set, the agent executes the full systematic literature review workflow: database queries with documented search strings, deduplication, abstract screening with PRISMA criteria applied consistently, full-text screening, data extraction with sentence-level attribution, and evidence table generation. Every action is logged with timestamp, input, output, and source. The human reviewer role shifts from executing each step to reviewing the agent's structured output and validating the methodology documentation.
Use Case 3, Protocol Design Intelligence Agent: Given a target indication and compound class, the agent queries the clinical trial landscape, comparator landscape, regulatory precedents, and patient population definitions, then generates a protocol design intelligence brief identifying the evidence bar the protocol must meet and the specific risks the current design should mitigate. The brief is traceable: every claim about the competitive landscape or endpoint standard links to a specific source in the knowledge layer.
Use Case 4, Dossier Currency Agent: An agent continuously monitors for new clinical, RWE, and regulatory evidence relevant to approved dossiers, flagging claims in existing dossier text that require updating based on new evidence, and generating structured update recommendations with source attribution. For HEOR teams managing products with ongoing post-market evidence generation, this agent transforms dossier maintenance from a periodic manual exercise into a continuous, alert-driven workflow.[8]
4. Autonomy With Accountability: The Pharma-Specific Governance Requirement
In regulated pharma environments, the governance framework for agentic AI is not optional. As the Pharmaceutical Technology interview with a leading pharma digital leader put it: autonomy without accountability is chaos, but accountability without autonomy is paralysis. The design choice for pharma agentic AI is always autonomy with accountability, and that balance is achieved through architecture, not through policy.[7]
Three non-negotiable governance requirements define safe agentic AI deployment in GxP environments. First, complete action logging: every action the agent takes must be logged with timestamp, input, output, and source, not summarised or sampled. The ability to reconstruct exactly what the agent did, in what order, using what data, is a regulatory requirement for any AI system that influences GxP-relevant outputs. Second, a governed knowledge layer as the operating environment: agents that operate on the open web or unstructured document repositories will hallucinate and propagate errors through multi-step workflows. An agent querying the Knolens knowledge graph cannot generate a fact not in the graph. It can only retrieve and present what is there, sourced and verified. Third, human-in-the-loop checkpoints at consequential decision points: agent autonomy is appropriate for data collection, classification, and synthesis. Human review and approval are required before any agent output influences a regulatory filing, clinical protocol decision, or strategic investment.[9]
5. The Six-Component Governance Framework for Pharma AI Agents
A complete governance framework for pharma agentic AI requires six components deployed before any agent is promoted to production use.[7]
Component 1, Agent identity and access management: Each agent has a defined identity with specific, scoped access permissions to the knowledge layer. Agents cannot access data beyond their authorisation level, and every access event is logged against the agent identity.
Component 2, Action logging and audit trail: Complete, timestamped logs of all agent actions, stored in a tamper-evident audit system with versioning. The audit trail must be sufficient to reconstruct the full agent workflow from goal initiation to output generation.
Component 3, Knowledge layer quality controls: The governed knowledge layer is the agent's ground truth. Source validation, entity resolution, and relationship accuracy controls are the primary defence against agent errors. An agent operating on a high-quality knowledge layer produces high-quality outputs. An agent operating on an unverified data source amplifies errors at speed.
Component 4, Output classification by downstream risk: Agent outputs are classified by the risk level of their downstream use. Low-risk outputs, covering data collection and classification, require review but not approval before use. High-risk outputs, covering regulatory filing inputs and clinical strategy recommendations, require formal human approval with documented rationale before any action is taken.[1]
Component 5, Error detection and gap flagging: When an agent encounters a query it cannot resolve from the knowledge layer because the answer is not in the graph, it must flag the gap rather than generate an approximation. Gap detection is as important as accuracy for regulated environments: a known unknown is manageable; a hallucinated answer to an unknown question is a compliance event.
Component 6, Agent performance monitoring: Ongoing measurement of agent accuracy, coverage, and latency. Periodic human audit of a random sample of agent outputs to identify systematic errors or coverage degradation. Performance benchmarks established at deployment are reviewed quarterly.
6. Why Agentic AI Needs a Knowledge Graph, Not RAG
The technical reason that agentic AI requires a knowledge graph foundation rather than a RAG architecture is compounding error propagation. In a multi-step agentic workflow, each step takes the output of the previous step as its input. If step three contains a hallucinated relationship between two clinical entities, step four incorporates that hallucinated relationship as a verified fact and builds further analysis on it. By step seven, the output contains embedded errors that are not flagged as uncertain because they were sourced from a prior step that appeared confident.[9]
Enterprise knowledge & AI memory platform architecture prevents this cascade. Because the knowledge graph stores facts as explicit, sourced entity-relationship triples, the agent cannot introduce a hallucinated relationship at any step in the workflow. When the agent retrieves a fact, it retrieves a specific triple with its source. When it generates an output, every claim in that output is traceable to a specific triple. The hallucination-prevention property is structural, not probabilistic, and it persists through all steps of a multi-step agentic workflow.[3]
This is the architectural reason why organisations building production-grade agentic AI for clinical, regulatory, and intelligence functions choose knowledge graph foundations over RAG. RAG reduces hallucination in single-step, simple queries. A knowledge graph eliminates it across multi-step agentic workflows.
7. Agentic AI in Competitive Intelligence: From Scheduled Reports to Continuous Briefings
The CI monitoring use case illustrates the practical transformation that agentic AI delivers most clearly. In a traditional CI function, analysts check sources on a scheduled basis, typically daily for high-priority signals and weekly for broader landscape monitoring. Coverage is limited by analyst bandwidth. Latency from signal appearance to CI team awareness is measured in days to weeks. For a Phase III readout in a competitive therapeutic area, a two-week latency is the difference between a proactive strategic response and a reactive one.[4]
An agentic AI expert intelligence layer on the Knolens platform monitors all relevant source types continuously. When a high-priority signal appears, the CI monitoring agent retrieves the relevant competitive context from the knowledge layer, generates a structured strategic impact assessment, and routes the alert to the appropriate team members within hours of the signal appearing. The CI analyst's role shifts entirely: from source-checking and data-gathering to strategic interpretation of pre-structured intelligence. Research consistently shows that this reallocation of analyst effort produces both higher coverage and higher analytical quality, because analysts can apply their expertise to interpretation rather than collection.[9]
8. How Fast Can Your Team Deploy Agentic AI on Knolens?
The reason 40% of agentic AI projects are cancelled, per Gartner, is not the agent technology itself. It is that organisations skip the knowledge layer and deploy agents on unstructured data or RAG pipelines that cannot support safe agentic operation. [1] Knolens solves this by shipping the knowledge layer as a pre-built product. You are not building the foundation before deploying agents. The foundation is already there.
Most pharma teams are running their first live agentic workflow on Knolens within six weeks of onboarding. Here is what that looks like.
Sprint 1, Weeks 1 to 2, Knowledge layer live and first agent activated: Knolens is connected to your target therapeutic area and data sources. Pre-built clinical ontologies, extraction pipelines, and source validation frameworks are activated. The knowledge layer is immediately queryable. The first agent, typically a CI monitoring agent for one therapeutic area or an SLR screening agent for one indication, is deployed on top of the live knowledge layer. Your team receives the first agent-generated output, a structured CI signal digest or a screened abstract set, within days. No infrastructure build required. [9]
Sprint 2, Weeks 3 to 4, Governance framework and human review workflow configured: Agent identity and access controls are configured. Action logging and audit trail systems are activated, creating a complete, timestamped record of every agent action from the first day of operation. Output classification tiers are set, low-risk outputs go directly to the team, high-risk outputs route through a human approval checkpoint before any downstream use. Error detection and gap flagging are configured so agents flag unknown queries rather than generating approximations.
Sprint 3, Weeks 5 to 6, Second use case and performance monitoring live: A second agent use case is deployed, such as a protocol design intelligence agent or a dossier currency monitoring agent, using the same governance framework established in Sprint 2. Performance monitoring dashboards are activated covering coverage rate, source fidelity, and human reviewer correction rate. Knolens clients operating knowledge-graph-grounded agents consistently report human reviewer correction rates below 2%. [9]
From Sprint 3 onward, agent scope expands sprint by sprint as the team's confidence and the knowledge layer's depth grow together. Multi-agent orchestration, where a CI monitoring agent feeds a landscape analysis agent which triggers a briefing generation agent, is introduced once the individual agents are operating reliably. Each new agent deploys with the governance framework already in place, not as a new infrastructure build. [4]
Five performance metrics define whether an agentic pharma AI deployment is delivering value and operating safely.[5]
Coverage rate: What percentage of relevant signals in the monitoring scope does the agent capture compared to a baseline human analyst? The target for a production CI monitoring agent is greater than 95% coverage relative to the manual baseline.
Speed: How quickly does the agent deliver a complete output from goal initiation? For a CI monitoring alert, the target is hours from signal appearance to structured alert delivery. For an SLR execution, the target is days from PICOTS definition to structured evidence table.
Source fidelity: What percentage of agent-generated claims are correctly attributed to the source from which they derive? For any agent producing outputs intended for regulatory or strategic use, the target should be 100%: every claim is attributable. A knowledge graph-grounded agent achieves this by architectural design.
Human reviewer correction rate: What percentage of agent outputs require substantive correction by human reviewers? Knolens clients operating knowledge-graph-grounded agents report correction rates below 2%, compared to 15 to 25% for agents operating on unstructured data or RAG-based architectures.[9]
Governance audit pass rate: What percentage of agent action logs satisfy the audit trail requirements for GxP-relevant outputs? This metric verifies that the governance infrastructure is functioning correctly as the agent scales to higher output volumes.
Conclusion
Agentic AI is not a future capability for pharma research. It is a 2026 deployment reality for the organisations that have built the right knowledge infrastructure underneath it. The 40% project cancellation rate Gartner predicts is not a reflection of a flawed technology. It is a reflection of organisations deploying agentic AI on foundations, unstructured data, RAG pipelines, and poorly governed knowledge bases, that cannot support it safely in regulated environments.[1]
Pienomial's Knolens platform provides the enterprise knowledge & AI memory platform and agentic AI knowledge layer that makes agentic pharma research safe, auditable, and scalable. Every agent query is grounded in verified, sourced facts. Every agent action is logged with complete provenance. Every output is traceable from claim to source. For pharma, HEOR, and CI teams ready to move from AI experimentation to AI infrastructure, this is the foundation that separates production-grade agentic AI from cancelled pilots. [9] CTA: Explore Agentic AI for Pharma Research, request a KnolForge demo.
